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Abstract

t

Pulmonary Hypertension (PHT) is relatively common, dangerous and under-recognised.
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Pulmonary hypertension is not a diagnosis in itself; it is caused by a number of differing
diseases each with different treatments and prognoses. Therefore, timely and accurate
recognition of the underlying cause for PHT is essential for appropriate management. This is
especially true for patients with Pulmonary Arterial Hypertension (PAH) in the current era of

an

disease-specific drug therapy.

Measurement of Pulmonary Vascular Resistance (PVR) helps separate pre-capillary from
PHT,

and

is

measured

with

right

heart

catheterisation

(RHC).

M

post-capillary

Echocardiography has been used to derive a number of non-invasive surrogates for PVR,

ed

with varying accuracy. Ultimately, the goal of non-invasive assessment of PVR is to separate
PHT due to left heart disease from PHT due to increased PVR, to help streamline

pt

investigation and subsequent treatment.

ce

In this review, we summarise the physiology and pathophysiology of pulmonary blood flow,

Ac

the various causes of pulmonary hypertension, and non-invasive surrogates for PVR.

Keywords: Pulmonary hypertension (PHT); Doppler echocardiography; Pulmonary arterial
hypertension; Pulmonary vascular resistance (PVR); Heart failure with preserved ejection
fraction

(HFpEF)
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Introduction

t

Pulmonary Hypertension (PHT), defined by a mean pulmonary artery pressure at or above 25

us
cr
ip

mmHg, can be broadly differentiated physiologically into pulmonary arterial hypertension
(PAH) due to increased pulmonary vascular resistance (PVR), PHT due to increased
pulmonary venous pressure but with a normal PVR (usually due to left heart disease), or a
combination of both abnormalities. This differentiation is a crucial step in the investigation of

an

patients with PHT, since the treatment of PHT due to left heart disease is fundamentally
different from PHT due to abnormally increased pulmonary vascular resistance. Simply

M

identifying the presence of PHT is necessary but not sufficient to manage such patients, and
measurement of PVR is a key step. However, assessment of PVR usually requires right heart

ed

catheterisation (RHC), which is invasive, has potential complications, and therefore not
universally performed in the investigation of PHT.

pt

Pulmonary hypertension is relatively common and associated with a high risk of death(1), yet

ce

often goes unrecognised for extended periods. Regardless of aetiology, the common
consequence of all forms of untreated PHT is symptomatic breathlessness, progressive right

Ac

ventricular failure and ultimately death. With the development of effective advanced therapy
for PAH, there is a need for simple non-invasive tools that can estimate PVR and help
identify patients who would benefit from more comprehensive investigation, including right
heart catheterisation. In this review, we will review and summarise the biochemical
compounds and mechanical variables that affect blood flow through the pulmonary
vasculature. We will also summarise techniques that have been used to non-invasively
estimate PVR.
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Physiology of Pulmonary Blood Flow and Pulmonary Vascular Resistance
Normal pulmonary circulation is low-pressure, low-resistance and highly dynamic, which

us
cr
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t

allows major increases in pulmonary blood flow in response to exercise with only small
increases in pressure. Pulmonary arterial blood flow regulation is maintained by pulmonary
vascular resistance and recruitment of additional pulmonary capillaries, without the option of
diversion through different vascular beds. This differs markedly from the systemic
circulation, in which exercise results in hyperaemia in skeletal muscles, flow-mediated

an

dilatation of conduit arteries, and dynamic changes in peripheral vascular resistance for each
relevant vascular bed.

M

The degree of pulmonary arterial tone, via smooth muscle contraction, is governed by a series
of vasoactive compounds released by the pulmonary vascular endothelium. Patients with

ed

PAH have increased levels of compounds that are responsible for vasoconstriction,
thrombosis and smooth muscle cell hyperplasia (2-4). Each of the compounds exerts different

pt

effects on vascular smooth muscle, endothelial cell, surrounding blood cell responses. These

Ac

ce

responses are summarised in Table 1.
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Table 1: Vasoactive compounds affecting pulmonary vascular resistance and drugs for PHT
targeting those compounds

t

Therapeutic agents modulating

Effects

us
cr
ip

Compounds

these compounds

Thromboxane A2

Vasoconstrictor, stimulator of

(TxA2)

platelet aggregation and

an

proliferation

aggregation and has

Epoprostenol, Iloprost

M

Vasodilator, inhibitor of platelet

Prostacyclin

None

antiproliferative property

ed

(counteracts thromboxane A2)
Potent vasoconstrictor and

(ET-1)

stimulator of pulmonary artery

pt

Endothelin-1

Endothelin receptor antagonists
(e.g. bosentan, macitentan)

Nitric Oxide

Vasodilator and inhibitor of platelet Inhaled NO
activation and vascular smooth-

Ac

(NO)

ce

smooth muscle cells proliferation

muscle cell proliferation,
counteracts endothelin-1’s actions

Phosphodiesterase inhibitors (e.g.
sildenafil) reduced the inactivation
of cyclic guanosine
monophosphate through which NO
mediates its effects
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Serotonin

No therapeutic agent available

Vasoconstrictor

t

currently

us
cr
ip

Pulmonary blood flow is further regulated via capillary recruitment. In states of resting
cardiac output, a number of capillary beds are in a collapsed state having neither blood
perfusion nor ventilation. As the CO increases, there is an increase in the capillary blood
volume resulting in recruitment of these distensible capillary beds without an increase in

an

PVR.

Despite the responsive nature of this system, many additional factors affect pressure through

M

the pulmonary vasculature. The Hagen-Poiseuille equation below describes the relationship

ed

between pressure, flow, viscosity and radius in a hollow, straight, non-distensible tube (5).

pt

= pressure change

ce

= length of pipe

= dynamic viscosity

Ac

= volumetric flow rate
= radius

The change in pressure across the pulmonary artery is inversely proportional to the fourth
power of the radius. If the radius of the pulmonary artery decreases (e.g. due to smooth
muscle hypertrophy, hypoxic vasoconstriction or pulmonary thromboembolic disease), there
is an accompanying disproportionate increase in the pressure across the pulmonary artery,
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and a higher up-stream pressure will be required in order to maintain normal down-stream
pressures.
There are additional effects on pulmonary pressures from blood viscosity (e.g. hyperviscosity

us
cr
ip

t

syndromes increase pulmonary pressures whereas anaemia decreases pulmonary pressures or
increased blood flow rates (high cardiac output or valvular disease).

Finally, the dynamics of blood flow in the left heart affect pulmonary blood flow. In a normal
heart, left ventricular relaxation during diastole is an active (ATP dependent) process, causing
a rapid fall in ventricular pressure and a “suction” effect on left atrial blood. This results in

an

relative emptying of the pulmonary vein blood into the left atrium, and a fall in pulmonary
capillary pressure. Further, during ventricular systole, the downward motion of the mitral

M

valve toward the ventricular apex elongates the left atrium creating a systolic “suction” effect
on pulmonary vein blood. Simultaneous right ventricular systolic contraction ensures a

ed

constant supply of blood into this low pressure circuit with rapid pulmonary capillary transit.
These events cause efficient systolic and diastolic pulmonary capillary blood transit.

pt

Conditions that decrease left ventricular and left atrial compliance such as chronic atrial

ce

fibrillation, the stiff left atrial syndrome(6, 7), left ventricular hypertrophy and restrictive
cardiomyopathy(8), disrupt the finely balanced transit through the pulmonary circulation and

Ac

increase pulmonary capillary pressures.
Measurement of Pulmonary Vascular Resistance
In humans in vivo, pulmonary haemodynamics are most accurately measured invasively using
right heart catheterisation. The mean pulmonary artery pressure (mPAP) can be measured by
averaging the pressure inside the pulmonary artery throughout the cardiac cycle. To measure
the pulmonary capillary wedge pressure (PCWP), the catheter is advanced into a branch
pulmonary artery, and a small balloon attached near the tip of the catheter is inflated until the
7
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pulmonary artery is occluded. The mean pressure measured at the tip of the catheter is taken
to be the back-pressure from the left heart, and approximates the left atrial pressure in the
absence of pulmonary vein stenosis. A mean PCWP <15 mmHg is generally accepted to

t

indicate normal left atrial mean pressure, and is required to diagnose PAH, excluding PHT

us
cr
ip

due to left heart disease(9).

The PVR is the resistance generated by the pulmonary vasculature against which the blood
must travel from right to left side of the heart and is influenced by the transpulmonary
gradient and the cardiac output:

TPG – Transpulmonary gradient

M

TPG = mPAP-PCWP

an

PVR = TPG/CO

mPAP – mean Pulmonary Artery Pressure in mmHg

ed

PCWP – Pulmonary Capillary Wedge Pressure in mmHg

pt

CO – Cardiac Output in L/min

In general, the higher the TPG and/or the lower the CO, the higher the PVR. Pulmonary

ce

vascular resistance is preferred to TPG, since it takes blood flow into account (10). The

Ac

equivalent measure in the systemic circulation, the systemic vascular resistance (SVR), is
generated by a number of different systemic arterial vascular beds and is approximately 10fold higher than the PVR. A normal PVR is 1–3 mmHg.min/L, and decreases further with
exercise and increased CO. For convenience, the mmHg.min/L units are often dropped and
presented as Wood Units (WU), in honour of Earl Wood, an early pioneer in the field.
Despite its importance in PHT diagnosis and management, RHC has a number of drawbacks.
It

is

invasive

with

potentially serious

risks

such

as

ventricular

arrhythmias,

thromboembolism, myocardial or valvular injury, pulmonary infarction and rupture of a
8
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pulmonary artery. Right heart catheterisation requires significant skills and standardisation of
the procedure, and is not universally available. Although RHC accurately measures the
PCWP, it may not reflect the true left ventricular filling pressure (11, 12), particularly if

us
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t

mitral stenosis (13), pulmonary vein stenosis or a noncompliant left atrium (6) is present.

Clinical Classification and Epidemiology of Pulmonary Hypertension

Pulmonary hypertension is defined as an increased resting mPAP at or above 25 mmHg,
measured with RHC (9). Pulmonary hypertension is not a disease in itself, but simply a

an

marker of a pathophysiological abnormality that requires explanation. A clinical
classification of PHT has been provided by the World Health Organisation (WHO) with

five groups, summarised in Table 2.

M

several more recent updates (14). The Latest Classification (NICE 2013) classified PHT into

ed

Table 2: NICE classification of pulmonary hypertension, with abridged examples for each

pt

group.

Group 1

ce

Pulmonary Hypertension Group

Ac

Pulmonary Arterial Hypertension

Examples
Idiopathic PAH
PAH associated with other diseases:
Scleroderma
Congenital heart disease
Myocardial disorders:

Group 2

Valvular heart disease

PHT due to Left Heart Disease
Congenital LV inflow or outflow obstruction
COPD and Interstitial lung disease
Group 3
Sleep disorders
PHT due to Lung Disease
Chronic hypoxia
Group 4

Multiple chronic pulmonary emboli
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Chronic Pulmonary
Disease (CTEPH)

Thromboembolic

Haematologic disorders

PHT with multifactorial cause

Chronic renal failure

us
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Group 5

The data from recent studies suggest the true prevalence of PHT in the general population is
higher than previously reported (15-17). We have previously reported a minimum ‘indicative’
prevalence for all forms of PHT at 326 cases/100,000 inhabitants of Armadale and its

an

surrounding area in Western Australia. Left heart disease-associated PHT was the commonest
cause (250 cases/100,000) and had the worst prognosis. Patients with PAH who were treated

M

with disease specific therapy had the best prognosis (18). Moreover, there is significant delay

ed

between symptom onset and the time of diagnosis leading to poor prognoses ( 19, 20).
Previously, patients with group 1 PHT (PAH) had worse survival than other groups. The era

pt

of advanced therapy has improved the overall prognosis of PAH patients (21) with some
trials suggesting one-year survival rates of 84% (22). Advanced therapy includes specific

ce

pulmonary vasodilator drugs, such as Prostacyclin, endothelin receptor antagonists (ERAs)
and phosophodiesterase type-5 (PDE-5) inhibitors. These decrease the rate of progression and

Ac

complications as well as improve symptoms associated with PAH, with the greatest benefits
derived from early commencement of therapy.

A Proposed Pathophysiological Classification of PHT based on PVR
The latest clinical classification for pulmonary hypertension only partially reflects the
underlying pathophysiology of each disease. For this reason, there is an overlap in treatment
between groups. An alternative method of classification is to describe the pathophysiology
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underpinning the PHT. Using this method, the causes of PHT can be subdivided into two
major groups: pre-capillary or post-capillary based on whether the pulmonary vascular
resistance is normal or increased. Pre-capillary PHT is defined by a high transpulmonary

t

gradient of at least 12 mmHg, a high pulmonary vascular resistance of >3 WU and

us
cr
ip

pulmonary capillary wedge pressures of <15 mmHg (normal left heart filling pressure). These
“high PVR” pulmonary hypertension patients may respond to pulmonary vasodilator therapy,
and would include individuals with Group 1 or Group 3 PHT. Some patients from groups 4 or
5 may also be included, depending on their PVR.

an

Post-capillary pulmonary hypertension, or “normal PVR” pulmonary hypertension, is
characterised by an increased PCWP of >15 mmHg but normal or low PVR(9, 10). These

M

patients are predominantly Group 2 (left heart disease).

Some patients have a mixed picture, with PCWP due to elevated LV filling pressures, but

ed

with coexisting increased PVR. These individuals have a disproportionate rise in their
pulmonary artery pressure beyond that expected from the degree of left heart disease alone.

pt

Such patients may respond only partially to diuretic therapy and treatment of their left heart
disease, however the use of pulmonary vasodilator therapy in this situation is

Ac

ce

controversial(23-26).
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The range of abnormalities are summarised in Figure 1 below.

B

C

D

pt

ed

M

an

us
cr
ip

t

A

ce

Figure 1: The range of abnormalities in PHT. Panel A shows a normal scenario with normal
PVR and normal LV filling pressures. Panel B shows normal LV filling pressures but

Ac

increased PVR resulting in PAH. Panel C demonstrates increased LV filling pressures with
normal PVR, resulting in pulmonary hypertension due to left heart disease. Panel D shows a
mixed picture, with increased LV filling pressure but a disproportionate increase in
pulmonary artery pressure caused by increased PVR. PVR = Pulmonary Vascular Resistance;
RVSP= right ventricular systolic pressure; LV= left ventricle.
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Identifying increased PVR and/or abnormal left heart filling pressure helps guide therapy,
particularly in the era of advanced therapies which target the pulmonary vasculature (27-32).
Heart failure with preserved ejection fraction (HFpEF) causing PHT due to increased filling

us
cr
ip

t

pressures should not be misclassified as PAH (33), particularly since some pulmonary
vasodilator therapy in this group of patients may be harmful.
Echocardiography in Pulmonary Hypertension

Echocardiography (echo) is the most commonly used noninvasive tool for identifying PHT,
and is particularly useful when screening for PHT (34). Using the velocity of tricuspid

an

regurgitation (TRV), pulmonary artery systolic pressure (PASP) can be estimated (35-37)
(Figure 2). There is a strong association between the pulmonary artery pressure (PAP)

Ac

ce

pt

ed

M

measured by right heart catheterisation and that obtained by echo (18, 38).

PASP = RAP + 4(TRV)2
Figure 2. From Apical 4-chamber view, the tricuspid regurgitation velocity (TRV) is
measured by using continuous wave Doppler. The PASP is estimated using the modified
Bernoulli equation (∆P=4V2). P=change in pressure, V=velocity of flow(36).
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Pulmonary Vascular Resistance Estimation with Echocardiography
A number of echocardiographic markers have been proposed for the noninvasive estimation
of PVR(39-42). However, many of these markers cannot reliably separate PHT due to left

t

heart disease from PHT due to increased PVR. Currently, there is no single reliable method

us
cr
ip

of estimating PVR non-invasively that has been tested and proven in a large-scale study.

As early as 1975, researchers have described methods to estimate PVR non-invasively. In a
study by Hirschfeld et al. (39), 64 patients with congenital heart disease underwent RHCs and
echo examinations. Fifty-seven patients had both examinations on the same day and four

an

patients had them within one month; however, three patients’ echoes were done three to five
years after RHC. The ratio of right ventricular ejection time (RVET) to right ventricular pre-

M

ejection period (RPEP) was found to correlate well with invasive measurements of
pulmonary artery diastolic pressure (PADP), PVR and mPAP. The correlation coefficient of

ed

the proposed index with PVR was 0.69. The study was limited to patients with congenital
heart diseases and extrapolation to PHT patients due to other aetiologies may not be

pt

appropriate. Dabestani et al. examined the pulmonary artery flow velocities by pulsed
Doppler echocardiography in 39 patients and found a negative linear correlation between

ce

pulmonary artery acceleration time and total pulmonary resistance(43).
Scapellato, and colleagues simultaneously performed Doppler echocardiographic and RHC

Ac

measurements in 63 patients with sinus rhythm and severe heart failure(40). Doppler
measurements from pulmonary flow and TRV curve were correlated with invasive PVR.
Among the investigated variables, the acceleration time of pulmonary systolic flow was
found to have best correlation with the invasive PVR (r=-0.68). The correlation coefficient
improved to 0.96 by using the equation:
PVR= -0.156+1.154*[(PEP/AcT) /TT]
PEP = Pre-ejection period
14
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AcT=Pulmonary acceleration time
TT= Total systolic time
The principal advantages of this study were simultaneous measurement of both echo and

t

RHC, and the relative simplicity and accuracy of their equation up to 9 WU. However, the

us
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study was small and excluded patients with atrial fibrillation and those without heart failure.

The formula described by Abbas et al. in 2003 is commonly used in echo laboratories as a
noninvasive PVR assessment. They performed simultaneous echo and RHC in 44 patients
(41). They found a close association (r=0.93, CI 0.87–0.96) between the invasively measured

an

PVR and the ratio of the TRV to the velocity time integral of the flow through the right
ventricular outflow tract (TVIRVOT,). Their equation approximated to the following:

M

PVRECHO =0.16 +10 x TRV/TVIRVOT

This method is easy to calculate from standard echo measurements, but the study was

ed

relatively small, did not include patients with PVR over 6 WU, and did not account for left
atrial pressure, an essential component of the invasively measured PVR. In subsequent

pt

analyses, the original Abbas equation was shown to underestimate invasive PVR assessment
in those with PVR over 6 WU(44), which could be partly corrected by incorporating

ce

assessment of LV filling pressures into the equation (using E:E’ ratios). The E:E’ ratio is

Ac

calculated as the ratio of the early diastolic flow through the mitral valve (measured using
pulsed wave Doppler echo) to the early diastolic descent velocity of the medial mitral annulus
(measured using pulsed wave tissue Doppler velocities). The E:E’ ratio is commonly used as
a surrogate for left ventricular filling pressure (45-47) and predicts mortality in left heart
disease(48-50). Using data from five separate studies, Abbas et al. demonstrated a more
robust association between PVR and TRV2/TVIRVOT (42), including patients with a PVR > 6
WU. The ratio has been further validated by a similar study in post-cardiac surgery patients in
an intensive care setting (51).
15
Page 15 of 22

A further study by Haddad et al. in 2009 demonstrated that invasively measured PVR
correlated well with the index of PASP to the heart rate (HR) times the TVIRVOT [PASP/(HR
x TVIRVOT)] in 51 patients with established PAH (52). This method is also simple to use and

t

the measurements required for the equation are routinely performed in most

us
cr
ip

echocardiography laboratories. The small number of participants again limited this study.
Additional sources of error include the need to estimate the right atrial pressure in their
equation.

Investigators and

an

Table 3: Summary of echocardiographic methods for estimating PVR
Surrogate Indexes/Formulae

ed

M

References

RVET/ RPEP

(39)

(RVET= right ventricular ejection

of

coefficient (r) of

patients

surrogate index with
PVR

64

0.69

63

0.96

pt

Hirschfeld et al.

Number Correlation

ce

time,

RPEP =right pre-ejection period.)
PVR=0.156+1.154*[(PEP/AcT) /TT]

Ac

Scapellato et al.
(40)

(PEP=Pre-ejection period,

AcT=Acceleration time,
TT=total systolic time of pulmonary
flow.)

Abbas et al.

TRV/TVIRVOT

(original) (41)

(VTR= Tricuspid Regurgitation

44

0.929 (95%
confidence interval
0.87 to 0.96)

Velocity,
16
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Velocity,
TVIRVOT=Time Velocity Integral of
the flow through the right ventricular

TRV/TVIRVOT (original)

(Analysis of raw

TRV2/TVIRVOT (modified)

150

0.76

patients

0.79

us
cr
ip

Abbas et al.

t

outflow tract)

on final

data from 5

analysis

validation

PASP/(HR x TVIRVOT)

51

0.860 (95%
confidence interval,
0.759-0.920)

ed

M

Haddad et al. (50)

an

studies)(42)

Recently, a new echocardiographic method for estimating transpulmonary gradients has been

pt

proposed by Scalia et al. (53). The ePLAR, or echocardiographic pulmonary to left atrial ratio
is the ratio of peak tricuspid regurgitation velocity (a marker of pulmonary artery systolic

Ac

ce

pressure) and E:E’ ratio (a marker of left ventricular filling pressure).

ePLAR = Echocardiographic Pulmonary to Left Atrial Ratio
TRV = Tricuspid Regurgitation Velocity
= The ratio of transmitral E-wave to septal mitral annular Doppler Tissue Imaging E'wave
The marker is simple, non-invasive, and uses measurements performed as part of a standard
echocardiogram. For 16,356 “normal” echocardiograms without PHT, the mean ePLAR was
17
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0.30 +/- 0.09m/s. For 133 patients with PHT, the ePLAR helped separate those with elevated
PVR from those with PHT due to left heart disease: In 35 patients with pre-capillary PHT
confirmed using RHC (with elevated PVR, mean 6.5+/-3.6 WU), the mean ePLAR was 0.44

t

+/- 0.22 m/s. The ePLAR was significantly lower (0.18 +/- 0.18 m/s) in those with PHT due

us
cr
ip

entirely to left heart disease (81 patients, mean PVR 3.1+/-2.7 WU). The major limitation of
the study is non-simultaneous performance of echocardiograms and RHC. Although helpful
to identify patients with elevated transpulmonary gradients, ePLAR does not take cardiac

an

output into account.

Conclusions

M

Pulmonary hypertension is common and associated with significant mortality. A rigorous
approach to its diagnosis is required by every echo laboratory, starting with estimation of

ed

pulmonary artery pressure. Pulmonary hypertension is not a diagnosis in itself, and
identification of the underlying cause will determine approaches to treatment. Estimation of

pt

PVR is an important aspect of the diagnostic workup and a number of non-invasive methods
for PVR measurement have been proposed. Like their invasive counterparts, most non-

ce

invasive methods rely on a combination of pulmonary artery pressure and flow assessment;
however, most studies describing these methods suffer from small sample study size, limited

Ac

reliability across a broad range of patients, and do not take left atrial pressure into account.
New methods such as ePLAR show promise, but require further study in large cohorts with
differing forms of pulmonary hypertension.
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